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PURPOSE: The objectives were to determine the effects of oral contraceptives and the 
menstrual cycle on the benefits of caffeine supplementation for cycling performance. 
METHODS: Seventeen recreationally trained female cyclists, oral contraceptive users 
(n=9) and non-users (n=8), completed four trials consisting of 3-km time trials (TT). 
Subjects ingested either 6mg/kg of caffeine or a placebo one hour prior to each trial. 
Magnitude based inferences were used to evaluate treatment differences. RESULTS: 
***TBD. CONCLUSIONS:*** TBD.  
  
INTRODUCTION 
 Caffeine is often consumed for its stimulating effects and ability to improve 
physical performance (5). There is good evidence that caffeine supplementation can 
enhance physical performance ranging from peak strength to endurance performance (3–
5, 10, 15, 20, 22, 49, 51, 55, 56).  The optimal caffeine dose for performance benefits is 
between 3 and 6 mg of caffeine per kilogram of body mass (13, 20, 22, 51).  
The pharmokinetics of caffeine is predominantly regulated by hepatic cytochrome 
P450 (CYP1A2), the enzyme responsible for metabolizing the majority of caffeine (17, 
37, 40, 41, 52, 59). Therefore, different concentration/activity levels of CYP1A2 
represents a major source of variability in the pharmacokinetics of caffeine (58). 
Demethylation is the first step to caffeine metabolism, and is mostly metabolized to form 
paraxanthine (29). Less is known about paraxanthine kinetics and its potential role in 
facilitating beneficial effects of caffeine on exercise performance (10), however, caffeine 
metabolites have an even higher affinity for the adenosine receptors, which stimulate the 
central nervous system (11, 18), thereby plausibly having an even greater effect on 
performance than caffeine itself.  
 The rate of caffeine metabolism is not only sensitive to genetic variations of the 
enzyme, but also biological sex (5, 29); specifically, female sex hormones, estrogen and 
estradiol (1, 2, 17, 23, 42). There is an evident trend for higher plasma caffeine and lower 
plasma paraxanthine concentrations in women compared to men, suggesting that women 
metabolize caffeine slower than men (6). Women with higher estrogen levels, [such as 
oral contraceptive steroid (OCS) users, females in the luteal phase, or pregnant], have 
been found to have decreased CYP1A2 activity and decreased caffeine clearance (2, 32, 
42).  Despite the varying clearance rates across the menstrual cycle, currently nothing is 
known about whether or not this impacts the performance response to caffeine intake. 
Therefore, one of the primary aims of this study was to test the hypothesis that there will 
be a magnified effect of caffeine on performance in the follicular phase compared to the 
luteal phase. 
 The use of hormonal contraceptives is another condition when estrogen levels are 
elevated, (50), possibly effecting the ergogenic effect of caffeine through dampening the 
rate of caffeine metabolism. Chronic OCS use has been previously associated with 
impaired metabolism of caffeine (1, 2, 40, 43, 47, 53). It is commonly reported that 
OCS’s inhibit CYP1A2 activity (1, 2, 25, 43, 44, 53). OCS’s appear to modify the 
metabolism of caffeine by reducing the formation of paraxanthine, which is the primary 
pathway of caffeine metabolism, possibly limiting its physiological effects (44). There is 
no current evidence of the interactive effect OCS use has on the ergogenic effect of 
caffeine. Therefore, the second aim of this project is to test the influence of OCS use on 
the performance response to caffeine supplementation compared to non-OCS users. 
METHODOLOGY 
Subjects 
 Twenty-eight healthy, recreationally trained female cyclists (15 OCS users, 13 
non-users) from James Madison University and the greater Harrisonburg/ Rockingham 
County area volunteered for the study. However, seven OCS users and four non-users 
withdrew from the study due to injuries, Lyme disease diagnosis, switching birth control 
prescription, seasonal flu, vasovagal syncope, or scheduling difficulties. Inclusion criteria 
included: female, 18-35 years of age, non-smokers, cycle ≥ 30 minutes at least two days a 
week, and VO2max ≥ 40 ml/kg/min. Further, subjects were required to be eumenhorreic 
with menstrual cycle length between 21-35 days over the past 6 months. Descriptive data 
are shown in Table 1.0.  Subjects who are not on any form of contraception will be 
assigned to the control group (n=15), and the subjects on monophasic or tri-phasic oral 
contraceptives will be assigned to the OCS user group (n=15). In the OCS user group, 
subjects were limited to monophasic oral contraceptives or tri-phasic oral contraceptives 
containing ethinyl estradiol and levonorgesterel for at least 6 months (8). Subjects were 
fully informed about the experimental procedures and possible risks before given written 
informed consent. Informed consent included information of the experimental procedures 
and risks prior to participation. James Madison University Institutional Review Board 
approved this study. 
Experimental Design 
Subjects reported to the laboratory for two familiarization trials and four 
experimental trials. Two experimental trials (1 placebo and 1 caffeine) were conducted 
during the luteal phase and two experimental trials (1 placebo and 1 caffeine) were 
performed in the follicular phase of the menstrual cycle. The luteal phase trials were 
performed from days 7 to 13 of the menstrual cycle, and the follicular phase trials were 
performed from days 18 to 24. Each treatment trial was performed in the morning 
between 6:00am and 10:00am. Trials were separated by at least 48 hours.  
Preliminary Testing 
Following height and body mass measurements, VO2max was assessed during an 
incremental test on a bicycle ergometer (Velotron™ cycle ergometer, Racermate, Inc. 
Seattle, WA, USA). Workload started at 50 W and was increased in 25 W increments 
every minute until volitional fatigue, or pedaling rate dropped below 50 rpm for >10 
seconds. Breath samples were collected and oxygen consumption was analyzed with a 
Moxus® Modular Metabolic System (AEI Technologies, Pittsburgh, PA, USA).  VO2max 
was determined as the highest 30 second mean oxygen uptake value.  
Supplementation 
In a crossover, double-blind design, subjects were provided caffeine treatment or 
placebo. Anhydrous caffeine at 6mg/kg body weight was measured into opaque gelatin 
capsules. For placebo pills, gluten-free rice flour was put into opaque gelatin capsules. 
Supplementation was ingested with water, 60 minutes prior to the performance trial.  
Familiarization Trials 
Two familiarization trials were completed on a Velotron™ cycle ergometer 
before each subject began experimental trials. A 5-min self-selected warm-up was 
performed before all 3-km time-trials. Subjects were instructed to approach the time trial 
as a competition, emphasizing the importance to perform each trial as a race and put forth 
100% effort. All trials were completed without verbal feedback and only elapsed distance 
was displayed.  The familiarization trial protocol was identical to the performance trials 
with the exception of caffeine/placebo supplementation. 
Performance Trials 
Two venous blood samples were obtained; one upon arrival to the laboratory for 
baseline caffeine measures and another 60 minutes post treatment, just prior to the 
exercise trial.  Following the second blood draw, subjects warmed-up on a treadmill for 5 
minutes at 3.5 mph, followed by the 3k-time trial on a Velotron cycle ergometer. Subjects 
were aware of the distance traveled and distance remaining during the trial, but were 
blinded to time and wattage output. Performance was recorded in time to complete and 
average watts for the 3-km time trial. 
Blood Analysis 
Approximately 3 ml of whole blood was obtained from an antecubital vein for 
measures of caffeine and estrogen concentrations.  Samples sat for 30 minutes to 
coagulate, and then spun in a refrigerated centrifuge (AccuSpin™) at 2500 rpm for 15 
minutes. Samples were subsequently decanted and plasma samples were stored in an -
80oC freezer for analysis of serum caffeine levels. 
Dietary and Exercise Control 
 Subjects completed 24-hour food logs and were instructed to replicate their diet 
for 24 hours prior to each subsequent trial. Subjects were asked to refrain from any food 
or drink (besides water) for four hours before and from caffeine and alcohol for 12 hours 
before each trial.  The OCS user group was required to authenticate intake of their 
respective oral contraceptive within the past 24 hours. In addition, 48-hour physical 
activity logs were completed prior to each trial, and were instructed to maintain 
consistent exercise habits between trials. Subjects were asked to refrain from any 
vigorous physical activity 12 hours prior to each trial.  
 
